Literature DB >> 115574

Isolation and identification of a human serum fibronectin-like protein elevated during malignant disease.

R G Parsons, H D Todd, R Kowal.   

Abstract

A human DNA-binding protein, designated MAD-2, has recently been found to be elevated in the serum from patients with malignant diseases. MAD-2 has been purified approximately 500-fold from peritoneal and pleural fluids collected from cancer patients. Immunodiffusion studies have indicated that MAD-2 is immunochemically identical to human plasma fibronectin. The purified material has been resolved by sodium dodecyl sulfate gel electrophoresis into two major protein chains with molecular weights in the range of 200,000 to 210,000 in either the presence or absence of disulfide bond-reducing agents. These results suggest that MAD-2 is a fibronectin fragment which has been generated through proteolysis. A quantitative assay system capable of detecting ng quantities of MAD-2 has been developed and used to verify the presence of elevated MAD-2 levels in DNA-binding protein fractions isolated from the serum of individuals with malignant diseases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 115574

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Pattern of fibronectin distribution in human lung cancer.

Authors:  H Nagai; M Isemura; H Arai; T Abe; S Shimoda; M Motomiya; H Sato; K Hashimoto; K Takusagawa; K Konno
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  [Fibronectin].

Authors:  E Klar; D L Heene
Journal:  Klin Wochenschr       Date:  1984-10-15

3.  Immunohistochemical study of fibronectin in human glioma and meningioma.

Authors:  N Kochi; E Tani; T Morimura; T Itagaki
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

4.  Transformation-enhancing activity of gelatin-binding fragments of fibronectin.

Authors:  G De Petro; S Barlati; T Vartio; A Vaheri
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

5.  Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.

Authors:  C Haglund; S Ylätupa; P Mertaniemi; P Partanen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Cellular fibronectin in serum and plasma: a potential new tumour marker?

Authors:  S Ylätupa; C Haglund; P Mertaniemi; E Vahtera; P Partanen
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.